arimoclomol has been researched along with pioglitazone in 2 studies
| Studies (arimoclomol) | Trials (arimoclomol) | Recent Studies (post-2010) (arimoclomol) | Studies (pioglitazone) | Trials (pioglitazone) | Recent Studies (post-2010) (pioglitazone) |
|---|---|---|---|---|---|
| 34 | 4 | 22 | 4,338 | 824 | 2,277 |
| Protein | Taxonomy | arimoclomol (IC50) | pioglitazone (IC50) |
|---|---|---|---|
| CDGSH iron-sulfur domain-containing protein 1 | Rattus norvegicus (Norway rat) | 1 | |
| Bile salt export pump | Rattus norvegicus (Norway rat) | 2 | |
| Peroxisome proliferator-activated receptor gamma | Rattus norvegicus (Norway rat) | 0.7 | |
| Bile salt export pump | Homo sapiens (human) | 0.337 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 0.114 | |
| Steryl-sulfatase | Homo sapiens (human) | 0.8 | |
| Peroxisome proliferator-activated receptor alpha | Mus musculus (house mouse) | 1.15 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.298 | |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 3.0379 | |
| Peroxisome proliferator-activated receptor gamma | Mus musculus (house mouse) | 0.7 | |
| CDGSH iron-sulfur domain-containing protein 2 | Homo sapiens (human) | 4.8 | |
| CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | 8.65 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Demcáková, E; Klimes, I; Koranyi, L; Kürthy, M; Mogyorosi, T; Nagy, K; Seböková, E; Ukropec, J | 1 |
| Bíró, K; Jednákovits, A; Kukorelli, T; Kürthy, M; Mogyorósi, T; Nagy, K; Tálosi, L | 1 |
2 other study(ies) available for arimoclomol and pioglitazone
| Article | Year |
|---|---|
Comparison of the extrapancreatic action of BRX-220 and pioglitazone in the high-fat diet-induced insulin resistance.
Topics: Animals; Dietary Fats; Hydroxylamines; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Muscle, Skeletal; Pancreas; Pioglitazone; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones | 2002 |
Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models.
Topics: Animals; Diabetic Neuropathies; Guanidines; Hydroxylamines; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Pioglitazone; Rats; Rats, Wistar; Rats, Zucker; Streptozocin; Thiazoles; Thiazolidinediones | 2002 |